Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23557952 | 0.90 | MAPT (0.41) | MAPTAKT1KMT2AKDM4EALDH1A1 | |
| SCHEMBL23558365 | 0.89 | ABL1 (0.35) | MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL23558305 | 0.89 | PGR (0.38) | MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL23558074 | 0.85 | MAPT (0.34) | MAPTAKT1KDM4E | |
| SCHEMBL25863251 | 0.84 | MAPT (0.40) | MAPTAKT1KMT2AKDM4EALDH1A1 | |
| SCHEMBL25863181 | 0.84 | KDM4E (0.36) | MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL23558450 | 0.82 | GAA (0.35) | MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL25864026 | 0.82 | MAPT (0.31) | MAPTKDM4EALDH1A1 | |
| SCHEMBL23558229 | 0.82 | MAPT (0.31) | MAPT | |
| SCHEMBL23558288 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | MAPT 3799/4885AKT1 902/4885TDP2 2869/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | MAPT 3799/4885AKT1 902/4885TDP2 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.